Where the money went: management itemizes the period's spending into named growth uses tied to business already live
The model's full reasoning — Q4 2022 call → NOWe need to determine if management gives a concrete accounting of where the period's money and effort went, itemizing specific growth-directed uses, and ties those to already-real business. The transcript includes Bob Landry's financial guidance and commentary. He mentions R&D expense increased 43% driven by Libtayo transaction, full 50% share of antibody collaboration R&D, late-stage pipeline, clinical manufacturing, headcount. SG&A increased due to headcount, Libtayo commercialization, not-for-profit patient systems. He also mentions capital expenditures for manufacturing facilities, fill/finish, R&D expansion. He gives 2023 guidance. But does he tie these to already-real business? He mentions Libtayo commercialization, but that's tied to existing product. The spending is for ongoing operations and pipeline. The question asks if the spending is tied to business already real, like orders, customers, contracts, volumes. The transcript mentions EYLEA sales, Dupixent sales, Libtayo sales, but the spending is not specifically tied to those. The R&D increase is for pipeline, not for current revenue. The SG&A increase is for commercialization of Libtayo, which is already launched. But is that a step-up? The question asks if the period absorbed the cost of a step-up. The Libtayo transaction is a major change, but it's a one-time acquisition. The spending is not itemized as "we spent X on building capacity for Y which has Z orders." Management gives guidance but does not provide a detailed ledger of specific growth-directed uses tied to real business. They mention "higher headcount-related costs" but not specific. They mention "clinical manufacturing activities" but not tied to specific products with committed demand. The overall tone is not apologetic, but the spending is not itemized as a cost of growth already underway. The answer is likely NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| AES | The AES Corporation | Q1 2024 | 2024-05-03 | C+ |
| GIII | G-III Apparel Group, Ltd. | Q4 2024 | 2024-03-14 | C |
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| PUMP | ProPetro Holding Corp. | Q4 2023 | 2024-02-21 | C+ |
| HP | Helmerich & Payne, Inc. | Q1 2024 | 2024-01-30 | C |
| FSBC | Five Star Bancorp | Q3 2023 | 2023-10-31 | B |
| CMG | Chipotle Mexican Grill, Inc. | Q3 2023 | 2023-10-27 | B+ |
| OXM | Oxford Industries, Inc. | Q2 2023 | 2023-08-31 | C |
| PTLO | Portillo's Inc. | Q2 2023 | 2023-08-05 | B |
| ET | Energy Transfer LP | Q2 2023 | 2023-08-02 | C+ |
| CDE | Coeur Mining, Inc. | Q1 2023 | 2023-05-11 | C+ |
| CARS | Cars.com Inc. | Q1 2023 | 2023-05-06 | B |
| M | Macy's, Inc. | Q4 2022 | 2023-03-02 | D |
| CEIX | CONSOL Energy Inc. | Q4 2022 | 2023-02-07 | B |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| CIG | Companhia Energética de Minas Gerais | Q3 2022 | 2022-11-16 | C+ |
| SIBN | SI-BONE, Inc. | Q3 2022 | 2022-11-07 | C+ |
| SYY | Sysco Corporation | Q1 2023 | 2022-11-01 | C+ |
| CHE | Chemed Corporation | Q3 2022 | 2022-11-01 | B+ |
| TMCI | Treace Medical Concepts, Inc. | Q2 2022 | 2022-08-13 | B+ |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| IT | Gartner, Inc. | Q2 2022 | 2022-08-02 | A |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| CME | CME Group Inc. | Q2 2022 | 2022-07-27 | B |
| OGI | OrganiGram Holdings Inc. | Q3 2022 | 2022-07-14 | B+ |
| KFY | Korn Ferry | Q4 2022 | 2022-06-22 | B |
| FLYW | Flywire Corporation | Q1 2022 | 2022-05-14 | B+ |
| HLIO | Helios Technologies, Inc. | Q1 2022 | 2022-05-10 | C |
| CCRN | Cross Country Healthcare, Inc. | Q1 2022 | 2022-05-04 | B |
| FLUX | Flux Power Holdings, Inc. | Q2 2022 | 2022-02-10 | D |
| GTES | Gates Industrial Corporation plc | Q4 2021 | 2022-02-07 | C+ |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| KTB | Kontoor Brands, Inc. | Q3 2021 | 2021-11-04 | A |
| FFWM | First Foundation Inc. | Q3 2021 | 2021-10-26 | B |
| EHTH | eHealth, Inc. | Q2 2021 | 2021-07-29 | F |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| FSS | Federal Signal Corporation | Q1 2018 | 2018-05-12 | A |
| ATI | Allegheny Technologies Incorporated | Q1 2018 | 2018-04-24 | B |
| BCE | BCE Inc. | Q2 2017 | 2017-08-05 | B+ |
| FLEX | Flex Ltd. | Q1 2018 | 2017-07-28 | F |
| DAN | Dana Incorporated | Q1 2017 | 2017-05-02 | B |
| PSX | Phillips 66 | Q4 2016 | 2017-02-03 | C+ |
| TGI | Triumph Group, Inc. | Q2 2017 | 2016-11-03 | C+ |
| CHDN | Churchill Downs Incorporated | Q2 2016 | 2016-08-04 | C+ |
| LBTYK | Liberty Global's | Q1 2016 | 2016-05-10 | C+ |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
| SON | Sonoco Products Company | Q4 2015 | 2016-02-11 | B |
AES · Q1 2024 → YESThe question is: Does management give a concrete accounting of where the period's money and effort went, itemizing specific growth-directed uses tied to already real business? YES Management itemizes the period’s spending in two places. - Utilities: “our Q1 investment was up nearly 100% from last year, as a result of the new rate structures and investing to improve system resilience and customer experience.” - Renewables: “we have also added almost 600 meg awatts of new projects to our operating portfolio” and “we remain fully on track to add a total of 3.6 gigawatts of new capacity this year” with “92% of the major equipment already on site” for 2024 projects. Both uses are explicitly tied to already-signed backlog ( 12.7 GW signed contracts, 1.
GTES · Q4 2021 → YESThe question is: Does management give a concrete accounting of where the period's money and effort went, itemizing specific growth-directed uses tied to already real business? YES The transcript shows management itemizing specific growth-directed uses—targeted incremental capacity investments, material science, and innovation—explicitly tied to already-real business: record backlog, book-to-build above 1, strong order rates, and committed wins (e.g., Gogoro, EV platform). These are framed as 2021 spending that consumed profitability and cash flow in Q4, directly supporting demand already arriving rather than future hope. While some operational headwinds (COVID, materials) are noted, the capacity investments are presented as the visible cost of growth underway.
DAN · Q1 2017 → YESThe question is about whether management gives a concrete accounting of where the period's money and effort went, specifically for growth-directed uses tied to already real business. YES Management itemizes concrete uses of the period’s cash and effort: higher capital spending to convert the $175 million backlog (Super Duty, Toyota HiLux, Jeep Wrangler readiness), the $25 million trade-payable settlement tied to the USM acquisition that is already supplying Dana, the Brevini integration costs 8 % organic growth plus aftermarket recovery, and the start-up costs of the new Toledo facility and Hungary gear plant that are supporting committed customer programs already in motion.